ArticleOxford medical case reports2025
Statin-induced immune mediated necrotising myopathy presenting with a markedly elevated cardiac troponin T in the absence of myocardial injury.
Article in Oxford medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac troponin (cTn) is a sensitive test to assess for myocardial injury. However certain clinical situations can result in a raised cTn in the absence of cardiac involvement. Here we present a case of a 65-year-old woman on long term atorvastatin who presented with generalised weakness, non-specific chest pain, and a persistently elevated high sensitivity cardiac troponin T. Upon further investigation acute myocardial injury was excluded and a diagnosis of statin-induced immune mediated necrotising myopathy (IMNM) was made. The patient improved with cessation of atorvastatin and initiation of immunosuppressive therapy with mycophenolate, intravenous immunoglobulin, and steroids. The mechanism for cTn elevation in skeletal myopathies without cardiac damage and the presentation and treatment of statin-induced IMNM are reviewed. We highlight the importance that in these cases the true cause of the raised cTn is recognised to allow prompt diagnosis and treatment of the underlying myopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.